Mesenchymal Stem Cell-Derived Exosomes

Phase 2Cell therapy

FFirst Affiliated Hospital of Guangxi Medical University

Mesenchymal Stem Cell-Derived Exosomes is one of 57 biologic programs targeting Oral Mucositis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Oral MucositisNot yet recruiting

Endothelial DysfunctionRecruiting

Oral MucositisPhase 2

Not yet recruiting

Endothelial DysfunctionPhase 2

Recruiting

Competition

Competitive Landscape

39 competitors in Endothelial Dysfunction

#DrugCompanyPhaseTrials

Avapro

Sanofi

Approved

2 2

Plavix

Sanofi

Approved

2 3

Onglyza

AstraZeneca

Approved

1 4

Brilinta

AstraZeneca

Approved

1 5

Zyloprim

Jazz Pharmaceuticals

Approved

1 6

Crestor

AstraZeneca

Approved

1 7

Ozempic

Novo Nordisk

Approved

1 8

Prevacid

Andriol

2 10

Jardiance

Boehringer Ingelheim

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 2Not yet recruiting

Oral Mucositis

NCT07312656

Clinical

Trials by Indication[1]

Oral Mucositis1 trial

Aerosolized Mesenchymal Stem Cell-Derived Exosomes for the Prevention and Treatment of Radiation-Induced Oral Mucositis

Not yet recruiting·FFirst Affiliated Hospital of Guangxi Medical University·Phase 2·NCT07312656·200 enrolled

Endothelial Dysfunction1 trial

MSC Exosome Therapy for Post-Preeclampsia Endothelial Dysfunction

Recruiting·UUniversitas Padjadjaran·Phase 1/2·NCT07183384·80 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Mesenchymal Stem Cell-Derived Exosomes. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Mesenchymal Stem Cell-Derived Exosomes compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Mesenchymal Stem Cell-Derived Exosomes. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — First Affiliated Hospital of Guangxi Medical University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 2[1]
Company: FFirst Affiliated Hospital of Guangxi Medical University

Mesenchymal Stem Cell-Derived Exosomes

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Oral Mucositis1 trial

Endothelial Dysfunction1 trial

References

Drug Info

Quick Facts

Related News